Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of anthelmintic agents against dirofilaria immitis

A kind of canine heartworm, selected technology, applied in the application field of anti-helminth agent against canine heartworm

Inactive Publication Date: 2017-05-10
INTERVET INT BV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, milbemycin should not be given as a prophylactic agent in dogs with high numbers of microfilariae without close monitoring

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of anthelmintic agents against dirofilaria immitis
  • Use of anthelmintic agents against dirofilaria immitis
  • Use of anthelmintic agents against dirofilaria immitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0240] In some embodiments, Z 1 is N. Such an embodiment consists of the following structures:

[0241] .

[0242] In some embodiments, Z 1 is selected from halogen, nitro, cyano, C 1 -C 6 -alkoxy and C 1 -C 6 - CH substituted by a substituent of alkylsulfanyl. The C 1 -C 6 -alkoxy and C 1 -C 6 -Alkylsulfanyl is optionally substituted with one or more independently selected halogen.

[0243] In some embodiments, Z 1 is CH substituted with an electron-withdrawing substituent. Such substituents include, for example, halo, nitro, cyano, halo-C 1 -C 6 -Alkyl, halo-C 1 -C 6 -alkoxy and halo-C 1 -C 6 - Alkylsulfanyl.

[0244] In some embodiments, Z 1 is CH substituted with halogen. For example, in some such embodiments, Z 1 is CH substituted by chlorine. These embodiments are comprised of the following structures:

[0245] .

[0246] In some embodiments, Z 1 is CH substituted by nitro. Such an embodiment consists of the following structures:

[0247]...

Embodiment 1

[0398] Example 1. Preparation of Analytical Protocols for Compounds of the Invention

[0399] Applicants have prepared a number of compounds for use in the present invention. Identity and purity were characterized and verified using various analytical high performance liquid chromatography ("HPLC") and mass spectrometry ("MS") protocols. These schemes are discussed below.

[0400] System I

[0401] In some cases, compound analysis was performed using a binary pump (G1312A) with a degasser (G1379A), a well plate autosampler (G1367A), a column oven (G1316A), a diode array detector (G1315B), a ESI-source mass spectrometer detector (G1946D SL) and evaporative light detector (Sedex 75) HPLC / MSD 1100 (Agilent, Santa Clara, CA, USA) were performed. The system uses four different columns and detection methods:

[0402] Plan I-A

[0403] The column used for this protocol was a Zorbax SB-C18 (Agilent) with 4.6 mm diameter, 30 mm length and 3.5 μm packing. The column was operat...

Embodiment 266

[0442] Further examples of compounds useful in the invention are described below. The first novel compound (Example 266) was prepared as follows:

[0443]

[0444] 4-[4-(Trifluoromethoxy)phenoxy]piperidine (2 g; 7.7 mmol) was suspended in dichloromethane (25 mL), and chloroacetic anhydride (1.35 g; 7.7 mmol) was slowly added with stirring ) in dichloromethane (5 mL). After 140 min reaction time, additional chloroacetic anhydride (575 mg; 3.3 mmol) was added and the reaction mixture was stirred overnight. The reaction mixture was washed with aq. 0.2M hydrochloric acid (2×30 mL) and aq. 1M sodium hydroxide (50 mL). The organic phase was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the desired crude product (2.1 g; 6.2 mmol), which was used as such in the next step.

[0445]

[0446] 2-Chloro-1-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]ethanone (23 g; 68 mmol) and 4-[4-nitro-3-( Trifluoromethyl)anilino]cyclohexanol (20.7 g; 68...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

This invention is directed to compounds and salts that are generally useful as agents to treat an infection with Dirofilaria immitis. This invention also is directed to treatments comprising the administration of the compounds and salts to animals in need of the treatments.

Description

[0001] field of invention [0002] The present invention relates to compounds and salts thereof generally useful as agents against Dirofilaria immitis. The invention also relates to treatments comprising administering said compounds and salts thereof to an animal in need thereof. [0003] Background of the invention [0004] Heartworm infection is caused by the filarial organism Heartworm caninum. At least 70 species of mosquitoes can serve as intermediate hosts; Aedes, Anopheles, and Culex are the most common vector genera. Patent infection is possible in many wild and companion animal species. The wildlife library includes wolves, coyotes, foxes, California gray seals, sea lions and raccoons. Among companion animals, heartworm infection is primarily diagnosed in dogs and less commonly in cats and ferrets. Heartworm disease has been reported in most countries with temperate, subtropical, or tropical climates, including the United States, Canada, Australia, Latin America, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/451A61K31/496A61P33/10
CPCA61K31/451A61K31/496A61K31/445A61P33/10
Inventor C.P.A.查斯赛宁J.鲁茨A.R.赫克罗斯
Owner INTERVET INT BV